| Name | Tetrac |
| Description | Tetrac (Tetraiodothyroacetic acid) is a derivative of L-thyroxine (T4), a thyroxine integrin receptor antagonist.Tetrac induces antiproliferation by blocking EGFR-mediated cell signaling in colorectal cancer cells.Tetrac blocks the effects of T4 and 3,5,3'-triiodo-L-thyronine (T3) on the cell-surface thyroxine integrin αvβ3 receptors.Tetra has anti-angiogenic, anti-tumor activity and pro-apoptotic activity. |
| In vitro | Tetrac (0.01-1 μM; 2-6 d) induces anti-proliferation in HT-29 and HCT116 cells with different K-RAS status, inhibits ERK1/2 activation (0.1 μM; 30 min), and modulates expression of CCND1, c-Myc, CASP2, and THBS1 (0.1 μM; 24 h), as demonstrated by cell proliferation assays in HT-29 and HCT116 cells[3]. |
| In vivo | Tetrac (35 μg/day; p.o.; for 40 days; Wild-type male Balb/C mice inoculated with 102B16F10 or B16LS9 cells) delayed the onset of ocular melanoma and reduced the S-100 and integrin staining levels. Tetrac can inhibit tumor inoculation, growth, and integrin expression in mice.[4] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 45 mg/mL (60.17 mM), Sonication is recommended.
|
| Keywords | Tetrac |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin | Gefitinib |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
